In addition, deguelin not only inhibited the CCL2/NF-κB signaling pathway, but also exogenous supplementation of CCL2 could partially reverse the growth inhibitory effect of deguelin on GBM cells by upregulating NF-κB activity. The gene discussed is NFKB1; the disease is glioblastoma.